Please use this identifier to cite or link to this item:
|Title:||"Ex-vivo" T-cell depletion in allogeneic hematopoietic stem cell transplantation: New clinical approaches for old challenges.|
adoptive cellular therapy
donor lymphocyte infusion
Graft vs Host Disease
Hematopoietic Stem Cell Transplantation
Killer Cells, Natural
Leukocyte Common Antigens
Neoplasm Recurrence, Local
|Citation:||Eur J Haematol.2021;(107)1:38-47|
|Abstract:||Allogeneic transplantation still remains as standard of care for patients with high-risk hematological malignancies at diagnosis or after relapse. However, GvHD remains yet as the most relevant clinical complication in the early post-transplant period. TCD allogeneic transplant is now considered a valid option to reduce severe GvHD and to provide a platform for cellular therapy to prevent relapse disease or to treat opportunistic infections.|
|Appears in Collections:||Fundaciones e Institutos de Investigación > FIB H. Infantil U. Niño Jesús > Artículos|
Files in This Item:
The file with the full text of this item is not available due to copyright restrictions or because there is no digital version. Authors can contact the head of the repository of their center to incorporate the corresponding file.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.